Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study

David E. Anderson, Sachin Kedar, Vijaya R. Bhatt, Kendra Schmid, Sarah A. Holstein, Matthew Rizzo

Research output: Contribution to journalArticle

Abstract

Background: Biomarkers of chemotherapy-related cognitive impairment (CRCI) in hematologic cancer are understudied and underdeveloped. We evaluated the feasibility of using ophthalmic and neurophysiologic markers to assess CRCI in hematologic cancer. Methods: Hematologic cancer patients either receiving (Ctx+) or not receiving (Ctx−) chemotherapy were recruited from a tertiary medical center. Demographically-matched healthy controls (HC) were also recruited. Ctx+ participants completed the following study visits: (1) after diagnosis but prior to chemotherapy (baseline); (2) after one treatment cycle (one-month post-baseline); and (3) after three treatment cycles (three-months post-baseline). Comparison subjects completed assessments at similar intervals. Participants completed: (1) neuropsychological assessments of attention and executive function; (2) neurophysiologic assessments of control over spatial attention and working memory; and (3) ophthalmic assessments of contrast sensitivity and optical coherence tomography (OCT). Results: We enrolled 45 participants (15 per group), and 30 participants (Ctx+ = 8; Ctx− = 10; HC = 12) completed all study visits. Ctx+ participants performed worse than HC participants on neuropsychological measures of attention and executive function. Both Ctx+ and Ctx− participants showed changes in neurophysiologic measures of control over spatial attention that differed from HC participants. Ctx+ participants showed chemotherapy-related declines in contrast sensitivity that were predicted by OCT retinal nerve fiber layer thickness (RNFL) changes. Changes in neurophysiologic measures of control over spatial attention were also predicted by OCT RNFL changes. Conclusion: We demonstrated the feasibility of using ophthalmic and neurophysiologic markers as rapid and non-invasive measures that may be useful for tracking CRCI in hematologic cancer.

Original languageEnglish (US)
Article number116644
JournalJournal of the neurological sciences
Volume410
DOIs
StatePublished - Mar 15 2020

Fingerprint

Feasibility Studies
Drug Therapy
Optical Coherence Tomography
Neoplasms
Contrast Sensitivity
Executive Function
Nerve Fibers
Healthy Volunteers
Short-Term Memory
Cognitive Dysfunction
Biomarkers
Therapeutics

Keywords

  • Cancer
  • Chemotherapy
  • Cognition
  • Contrast sensitivity
  • EEG
  • OCT

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer : A feasibility study. / Anderson, David E.; Kedar, Sachin; Bhatt, Vijaya R.; Schmid, Kendra; Holstein, Sarah A.; Rizzo, Matthew.

In: Journal of the neurological sciences, Vol. 410, 116644, 15.03.2020.

Research output: Contribution to journalArticle

@article{fafc66273a744faca60d2f152eed17d8,
title = "Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study",
abstract = "Background: Biomarkers of chemotherapy-related cognitive impairment (CRCI) in hematologic cancer are understudied and underdeveloped. We evaluated the feasibility of using ophthalmic and neurophysiologic markers to assess CRCI in hematologic cancer. Methods: Hematologic cancer patients either receiving (Ctx+) or not receiving (Ctx−) chemotherapy were recruited from a tertiary medical center. Demographically-matched healthy controls (HC) were also recruited. Ctx+ participants completed the following study visits: (1) after diagnosis but prior to chemotherapy (baseline); (2) after one treatment cycle (one-month post-baseline); and (3) after three treatment cycles (three-months post-baseline). Comparison subjects completed assessments at similar intervals. Participants completed: (1) neuropsychological assessments of attention and executive function; (2) neurophysiologic assessments of control over spatial attention and working memory; and (3) ophthalmic assessments of contrast sensitivity and optical coherence tomography (OCT). Results: We enrolled 45 participants (15 per group), and 30 participants (Ctx+ = 8; Ctx− = 10; HC = 12) completed all study visits. Ctx+ participants performed worse than HC participants on neuropsychological measures of attention and executive function. Both Ctx+ and Ctx− participants showed changes in neurophysiologic measures of control over spatial attention that differed from HC participants. Ctx+ participants showed chemotherapy-related declines in contrast sensitivity that were predicted by OCT retinal nerve fiber layer thickness (RNFL) changes. Changes in neurophysiologic measures of control over spatial attention were also predicted by OCT RNFL changes. Conclusion: We demonstrated the feasibility of using ophthalmic and neurophysiologic markers as rapid and non-invasive measures that may be useful for tracking CRCI in hematologic cancer.",
keywords = "Cancer, Chemotherapy, Cognition, Contrast sensitivity, EEG, OCT",
author = "Anderson, {David E.} and Sachin Kedar and Bhatt, {Vijaya R.} and Kendra Schmid and Holstein, {Sarah A.} and Matthew Rizzo",
year = "2020",
month = "3",
day = "15",
doi = "10.1016/j.jns.2019.116644",
language = "English (US)",
volume = "410",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer

T2 - A feasibility study

AU - Anderson, David E.

AU - Kedar, Sachin

AU - Bhatt, Vijaya R.

AU - Schmid, Kendra

AU - Holstein, Sarah A.

AU - Rizzo, Matthew

PY - 2020/3/15

Y1 - 2020/3/15

N2 - Background: Biomarkers of chemotherapy-related cognitive impairment (CRCI) in hematologic cancer are understudied and underdeveloped. We evaluated the feasibility of using ophthalmic and neurophysiologic markers to assess CRCI in hematologic cancer. Methods: Hematologic cancer patients either receiving (Ctx+) or not receiving (Ctx−) chemotherapy were recruited from a tertiary medical center. Demographically-matched healthy controls (HC) were also recruited. Ctx+ participants completed the following study visits: (1) after diagnosis but prior to chemotherapy (baseline); (2) after one treatment cycle (one-month post-baseline); and (3) after three treatment cycles (three-months post-baseline). Comparison subjects completed assessments at similar intervals. Participants completed: (1) neuropsychological assessments of attention and executive function; (2) neurophysiologic assessments of control over spatial attention and working memory; and (3) ophthalmic assessments of contrast sensitivity and optical coherence tomography (OCT). Results: We enrolled 45 participants (15 per group), and 30 participants (Ctx+ = 8; Ctx− = 10; HC = 12) completed all study visits. Ctx+ participants performed worse than HC participants on neuropsychological measures of attention and executive function. Both Ctx+ and Ctx− participants showed changes in neurophysiologic measures of control over spatial attention that differed from HC participants. Ctx+ participants showed chemotherapy-related declines in contrast sensitivity that were predicted by OCT retinal nerve fiber layer thickness (RNFL) changes. Changes in neurophysiologic measures of control over spatial attention were also predicted by OCT RNFL changes. Conclusion: We demonstrated the feasibility of using ophthalmic and neurophysiologic markers as rapid and non-invasive measures that may be useful for tracking CRCI in hematologic cancer.

AB - Background: Biomarkers of chemotherapy-related cognitive impairment (CRCI) in hematologic cancer are understudied and underdeveloped. We evaluated the feasibility of using ophthalmic and neurophysiologic markers to assess CRCI in hematologic cancer. Methods: Hematologic cancer patients either receiving (Ctx+) or not receiving (Ctx−) chemotherapy were recruited from a tertiary medical center. Demographically-matched healthy controls (HC) were also recruited. Ctx+ participants completed the following study visits: (1) after diagnosis but prior to chemotherapy (baseline); (2) after one treatment cycle (one-month post-baseline); and (3) after three treatment cycles (three-months post-baseline). Comparison subjects completed assessments at similar intervals. Participants completed: (1) neuropsychological assessments of attention and executive function; (2) neurophysiologic assessments of control over spatial attention and working memory; and (3) ophthalmic assessments of contrast sensitivity and optical coherence tomography (OCT). Results: We enrolled 45 participants (15 per group), and 30 participants (Ctx+ = 8; Ctx− = 10; HC = 12) completed all study visits. Ctx+ participants performed worse than HC participants on neuropsychological measures of attention and executive function. Both Ctx+ and Ctx− participants showed changes in neurophysiologic measures of control over spatial attention that differed from HC participants. Ctx+ participants showed chemotherapy-related declines in contrast sensitivity that were predicted by OCT retinal nerve fiber layer thickness (RNFL) changes. Changes in neurophysiologic measures of control over spatial attention were also predicted by OCT RNFL changes. Conclusion: We demonstrated the feasibility of using ophthalmic and neurophysiologic markers as rapid and non-invasive measures that may be useful for tracking CRCI in hematologic cancer.

KW - Cancer

KW - Chemotherapy

KW - Cognition

KW - Contrast sensitivity

KW - EEG

KW - OCT

UR - http://www.scopus.com/inward/record.url?scp=85077294613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077294613&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.116644

DO - 10.1016/j.jns.2019.116644

M3 - Article

C2 - 31901718

AN - SCOPUS:85077294613

VL - 410

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

M1 - 116644

ER -